Orchard Therapeutics prunes jobs to refocus priorities on bigger fruit
In 2018, Orchard Therapeutics secured access to GSK’s pioneering gene therapy for “bubble boy syndrome,” Strimvelis, among a basket of other rare disease programs, after the big British drugmaker decided the slate of drugs was too niche for its arsenal of treatments. Now, Orchard has also elected to steer away from “ultra-rare” diseases to programs focused on more prevalent conditions.
The strategic shift, which also includes halting construction of a Fremont manufacturing facility and shuttering its California R&D facility, has triggered a 25% cut in the company’s workforce.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters